OTCM
WPDPD
Market cap3kUSD
Apr 10, Last price
0.75USD
Name
WPD Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.57%
Rev. gr., 5y
%
Revenues
0k
Net income
-80k
L
CFO
-205k
L-94.02%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
IPO date
May 26, 2008
Employees
19
Domiciled in
CA
Incorporated in
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||